Quantitate amyloid, synuclein, and tau deposits

Use Case: Quantitate amyloid, synuclein, and tau deposits

Detect neuropathologies across brain regions: Examine the extent of naturally occurring pathologies in human brains afflicted with neurodegenerative disease.

Follow neuropathology progression: Study the biology of protein aggregate formation and spread across neural circuits in different animal models of neurodegenerative disease.

Monitor therapeutic efficacy: Measure the effect of therapeutic interventions on protein aggregate load in discrete regions of the brain for the treatment of various neurodegenerative diseases.

Figure 3 (Ref 5): CAA pathology and tau accumulation. (a) Tissue from donor AD 6 shows areas with leptomeningeal CAA pathology, (b) tissue from donor AD 5 shows a rare CAA-positive vessel, (c) frequent CAA-positive vessels were observed in donor AD 1, (d) closeup of the dashed box in b, (e) closeup of the dashed box in d. Article licensed under Creative Commons Attribution 4.0 International License.

For additional publications supporting this use case refer to:

Martorell et al. Cell 177(2), 256-271 (2019) – See Supplementary Figure 4g
Soula et al. Nature Neuroscience 26, 570–578 (2023) – Extended Data Figure 1
Chen et al. PNAS 120 (21) e2220684120 (2023) – See Figure 4b, Movie S1-2
Jiang et al. Frontiers in Neuroscience 20:18:1372297 (2024) – See Video 1-3
Hoglund et al. Acta Neuropathol 147, 101 (2024) – See Figure 3a-3g, Supplementary Movie 1

Our experienced team of application scientists have protocols to get you to data quickly with validated applications and can propose customized solutions for you for unvalidated applications. Fill the form below to get in touch with someone from the applications team today.